BDX Stock Recent News

BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.

If you can count, you may find healthcare stocks focused on the aging population to be a compelling opportunity. What do I mean?

The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' blood test tubes used in diagnosing bacterial and fungal infections.

Company Committed to Support Global Health and Customers BD Taking all Available Measures to Mitigate Supplier Issue FRANKLIN LAKES, N.J. , July 10, 2024  /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to a U.S. FDA letter to health care providers regarding the supply of blood culture vials: Nikos Pavlidis, worldwide president of BD Diagnostic Solutions said, "BD is experiencing reduced availability of blood culture vials from our supplier.

FRANKLIN LAKES, N.J. , July 10, 2024  /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1].

BD's (BDX) robust product portfolio raises optimism about the stock.

FRANKLIN LAKES, N.J. , July 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its third quarter of fiscal year 2024 on Thursday, August 1, 2024.

BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.

BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine FRANKLIN LAKES, N.J. , June 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.

FRANKLIN LAKES, N.J. , June 20, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates: Third Quarter Fiscal 2024 —Thursday, August 1, 2024 at 8:00 a.m.